For Ethically Minded Investors, International Stem Cell Corp. (ISCO) an Attractive Option

With their recent surge, biotechnology stocks have come to the attention of many investors, of whom many who are undoubtedly looking to see whether they could identify the next big biotechnological innovation and the surge in market performance along with it. But for investors concerned about the ethical side of their investments, these stocks may be a turn-off due to their potential to lead to what they consider to be medically unethical developments or other undesirable outcomes.

International Stem Cell Corp., a company that has been increasingly noted for its potential to bring about the next wave of innovation in this industry, offers those exploring this area for investment opportunities a moral advantage. The opportunity lies in the company’s powerful new stem cell technology, parthenogenesis. It uses unfertilized human eggs, or oocytes, to create parthenogenetic stem cells (hpSC stem cells) that can be used to treat millions of people with severe diseases of the eye, nervous system, or liver. Since these eggs are unfertilized, no viable embryo arises or undergoes destruction, allowing company investors to circumvent one of the hottest conflict focuses in medical ethics today.

As a whole, International Stem Cell Corp. focuses on developing and commercializing promising biotechnological solutions to today’s challenges in regenerative medicine. As parthenogenesis demonstrates, one of the channels by which the company seeks to foster new treatments is through development of new cell therapeutic solutions. Cell therapy has been clinically proven for treatment viability of serious afflictions in bodily locales including the already-mentioned eye, nervous system, or liver. However, it remains limited by the availability of safe immune-matched human cells. That is where parthenogenesis reveals its true value.

Specifically, the hpSC stem cells that this technology engenders can be immune-matched to millions of people. With just a relative small line number of hpSC lines, treatment solutions could potentially extended to a large percentage of the global population.

For more detailed information regarding the science behind parthenogenesis or International Stem Cell Corp.’s current biotechnological initiatives, please visit: www.internationalstemcell.com

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.

Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net

The Quality Stocks Daily Blog http://blog.qualitystocks.net

The Quality Stocks Daily Videos http://videocharts.qualitystocks.net

 The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net

Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net